In detail, PPARγ agonists, HDAC inhibitors, PI3K/AKT inhibitors and MEK/ERK inhibitors, have been recommended for NIS over-expression and have caused improved iodine uptake in thyroid cancers [121]. This evidence concerns the gene AKT1 and thyroid gland carcinoma.